NCT05186129View on ClinicalTrials.gov

Bioequivalence Study of Clopid® (Clopidogrel) 75 mg Tablet and Plavix® 75 mg Tablet After Oral Administration to Healthy Adult Subjects Under Fasting Condition

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

April 6, 2018

Primary Completion Date

April 15, 2018

Study Completion Date

April 20, 2018

Conditions
Bioequivalence
Interventions
DRUG

Clopid® 75 mg Tablet

Single dose of Clopid® 75 mg Tablet (Clopidogrel) was administered after a 10-hour overnight fast.

DRUG

Plavix® 75mg Tablet

Single dose of Plavix® 75 mg Tablet (Clopidogrel) was administered after a 10-hour overnight fast.

Trial Locations (1)

75270

Center for Bioequivalence Studies and Clinical Research (CBSCR) ICCBS, University of Karachi, Karachi

Sponsors
All Listed Sponsors
collaborator

Ferozsons Laboratories Ltd.

INDUSTRY

lead

Center for Bioequivalence Studies and Clinical Research

OTHER

NCT05186129 - Bioequivalence Study of Clopid® (Clopidogrel) 75 mg Tablet and Plavix® 75 mg Tablet After Oral Administration to Healthy Adult Subjects Under Fasting Condition | Biotech Hunter | Biotech Hunter